Pentoxifylline and antiaggregants in recent transient ischemic attacks
Completed
Phase N/A ResultsTrial Description
To study the preventive capacity of a combination of acetylsalicylic acid and dipyridamole and of pentoxifylline in the reduction of morbidity rates in patients with recent TIAs.
Interventions
- Dipyridamole (Persantine®)Drug
Intervention Desc: Platelet aggregation inhibitor - Pentoxifylline (Trental®)Drug
Intervention Desc: Vasodilator. In addition, may reduce viscosity or improve erythrocyte flexibility.
Trial Design
Randomized trial of 66 patients at 4 centers.
Patient Involvement
Patients were randomized to receive either acetylsalicylic acid and dipyridamole (1,050 mg + 150 mg/day) or pentoxifylline (1,200 mg/day). Treatment was continued and patients were followed up monthly for one year.
Outcomes
Type | Measure | Time Frame | Safety Issue |
---|---|---|---|
Primary | Recurrent ischemic event. |
Recruitment
- Gender: Both
- Study Size: 66
- Number of Centers: 4
- Max Time from Onset: 1 Months
- Follow Up: 1 Years
Principal Investigator
-
Ernesto Herskovits
Buenos Aires, Argentina.
Locations
- Buenos Aires, Argentina